Bosentan influence on catecholamines levels in patients with idiopathic arterial pulmonary hypertenson

E. Kobal, T. Martynyuk, O. Arkhipova, V. Masenko, S. Nakonechnikov, I. Chazova (Moscow, Russian Federation)

Source: Annual Congress 2012 - Pulmonary circulation: clinical PAH, registries and treatments
Session: Pulmonary circulation: clinical PAH, registries and treatments
Session type: Thematic Poster Session
Number: 953
Disease area: Pulmonary vascular diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
E. Kobal, T. Martynyuk, O. Arkhipova, V. Masenko, S. Nakonechnikov, I. Chazova (Moscow, Russian Federation). Bosentan influence on catecholamines levels in patients with idiopathic arterial pulmonary hypertenson. Eur Respir J 2012; 40: Suppl. 56, 953

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Bosentan influence on cellular immunity parameters in patients with idiopathic arterial pulmonary hypertension
Source: Annual Congress 2012 - Clinical management of lung diseases: from bronchi to pleura
Year: 2012

Changing serum cytokines levels in patients with idiopathic pulmonary arterial hypertension treated with bosentan
Source: Annual Congress 2012 - Clinical management of lung diseases: from bronchi to pleura
Year: 2012

Long-term efficacy of bosentan in treatment of pulmonary arterial hypertension in children
Source: Eur Respir J 2011; 37: 70-77
Year: 2011



Plasma big-endothelin and hemodynamics in patients with pulmonary arterial hypertension compared to patients with chronic left heart failure with and without pulmonary venous hypertension
Source: Annual Congress 2009 - Pulmonary circulation I
Year: 2009

Peripheral airway dysfunction persist after endothelin receptor antagonist therapy in patients with idiopathic pulmonary arterial hypertension
Source: Annual Congress 2009 - Pulmonary circulation
Year: 2009


Endothelin-1 and endothelin-3 plasma levels in severe idiopathic pulmonary arterial hypertension
Source: Annual Congress 2005 - Pulmonary hypertension: pathophysiology
Year: 2005


Increased renin-angiotensin-aldosteron system activity in lungs of patients with idiopathic pulmonary arterial hypertension
Source: Annual Congress 2011 - Clinical characteristics of patients with pulmonary hypertension
Year: 2011


Evaluation of serum cytokines in patients with idiopathic pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension with hypercholesterolemia
Source: International Congress 2017 – PAH and CTEPH
Year: 2017


Diagnosis of pulmonary arterial hypertension in patients with idiopathic pulmonary fibrosis
Source: Eur Respir J 2005; 26: Suppl. 49, 335s
Year: 2005

Exercise pathophysiology in patients with pulmonary arterial hypertension
Source: Annual Congress 2007 - Mechanisms of exercise intolerance in cardiorespiratory disease
Year: 2007


Pulmonary function in patients with idiopathic pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
Source: Annual Congress 2010 - Pulmonary circulation I
Year: 2010

Treatment of early systemic sclerosis associated pulmonary arterial hypertension with endothelin receptor antagonists improves survival
Source: Annual Congress 2007 - Clinical aspects of pulmonary arterial hypertension
Year: 2007



Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension
Source: Eur Respir J 2006 Oct 01;28(4):691-694
Year: 2006



Effect of sitaxentan in patients with pulmonary arterial hypertension associated to congenital heart diseases
Source: Annual Congress 2009 - Pulmonary vascular diseases
Year: 2009

Long-term effects of bosentan in patients with HIV-associated pulmonary arterial hypertension
Source: Eur Respir J 2009; 33: 92-98
Year: 2009



Patterns of mean pulmonary artery pressure (mPAP)-flow relation changes following chronic therapy in idiopathic pulmonary arterial hypertension (IPAH)
Source: Eur Respir J 2006; 28: Suppl. 50, 427s
Year: 2006

Acute haemodynamic effects of adaptive servoventilation therapy in patients with pulmonary arterial hypertension and patients with chronic thromboembolic pulmonary hypertension
Source: International Congress 2015 – Pulmonary hypertension: management
Year: 2015

Differential response to the addition of sildenafil to bosentan monotherapy between idiopathic and scleroderma-associated pulmonary arterial hypertension
Source: Eur Respir J 2006; 28: Suppl. 50, 547s
Year: 2006

Beyond arterial remodelling: pulmonary venous and cardiac involvement in patients with systemic sclerosis-associated pulmonary arterial hypertension
Source: Eur Respir J 2010; 35: 6-8
Year: 2010


The role of fractalkine in idiopathic pulmonary arterial hypertension
Source: Annual Congress 2009 - Pathobiology of pulmonary vascular diseases
Year: 2009